Lightspeed Venture Partners
A Principal Scientist in Formulation Development leading the design and optimization of drug product formulations. This role involves hands-on experimental work, technical execution, and cross-functional collaboration to support research, clinical development, and innovation in pharmaceutical formulations.
Headquarters
Menlo Park, California, United States
Company Size
51-200 employees
Founded
2000
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends. It backs founders from seed through growth, providing capital, strategic guidance, and operational support to scale high-impact companies across consumer and enterprise technology and adjacent sectors. With a global footprint, Lightspeed partners for the long term to help companies grow into category leaders.
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases
Jun 10, 2025
Scorpion spinout raises $177M to advance preclinical assets after 2 clinical programs sold to Pierre Fabre
Jun 10, 2025
Scorpion, fresh off Lilly deal, spins out startup Antares
Jun 10, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Lightspeed Venture Partners.
Scorpion spin-off Antares launches with $177 million
Jun 16, 2025
Principal Scientist Formulation
Sanofi
Scientist, Formulation Development
Integrated Resources INC
Senior Scientist Formulation and Process Development
Insmed Incorporated
Formulation Research Scientist
Vertex
Scientist II, Drug Product Development
WuXi Biologics
Associate Principal Scientist in Oral Formulation Sciences
Merck & Co., Inc.